Source: ERS Course 2015
Disease area: Respiratory critical care



Rating:

Share or cite this content

Citations should be made in the following way:
M. Witzenrath (Berlin, Germany). From target to preclinical evidence: the “Pneumonia and ARDS” experience. ERS Course 2015

Member's Comments

No comment yet.

Related content which might interest you: From target to preclinical evidence : the “Lung fibrosis” experience Source: ERS Course 2015 Year: 2015 Early outcomes in CAP: clinical stability, clinical failure and nonresolving pneumonia Source: Eur Respir Monogr 2014; 63: 205-218 Year: 2014 Biomarkers and VAP: results and perspectives Source: Eur Respir Mon 2011; 53: 24-35 Year: 2011 Pneumonia severity assessment scores in COVID19 pneumonia; clinical validation in a pragmatic healthcare setting Source: Virtual Congress 2021 – COVID - 19: lessons learned Year: 2021 Pneumonia in the context of severe sepsis: a significant diagnostic problem Source: Eur Respir J 2008; 32: 1417-1418 Year: 2008 Pneumonia in exacerbations of COPD: what is the clinical significance? Source: ERJ Open Res, 6 (1) 00282-2019; 10.1183/23120541.00282-2019 Year: 2020 A survey on the use in clinical practice of noninvasive positive pressure ventilation (NPPV) as a first-line intervention for acute respiratory distress syndrome (ARDS) Source: Annual Congress 2013 –NIV in the acute setting: growing experience and novel applications Year: 2013 Management-based risk prediction in community-acquired pneumonia by scores and biomarkers Source: Eur Respir J 2013; 41: 974-984 Year: 2013 Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: A randomized clinical trial Source: International Congress 2015 – Acute critical care: news from the ICU Year: 2015 Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research Source: Eur Respir J, 49 (6) 1700051; 10.1183/13993003.00051-2017 Year: 2017 The role of procalcitonin in predicting severity and clinical course of aspiration pneumonia Source: International Congress 2015 – CAP: prognostic factors in frail patients Year: 2015 Acute respiratory failure and severe sepsis may identify different clinical phenotypes in community-acquired pneumonia Source: Annual Congress 2013 –Interesting research questions Year: 2013 Can procalcitonin or C-reactive protein predict supporative lung complications and ARDS at severe community-acquired pneumonia (CAP)? Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment Year: 2016 Salmeterol prevents pneumonia and reduces biomarkers of inflammation/epithelial damage but not acute lung injury following oesophagectomy-the results of BALTI-prevention trial Source: Annual Congress 2013 –Acute lung injury: novel clinical and experimental insights Year: 2013 Exacerbation and pneumonia risk models: methodology and results from the IMPACT trial Source: International Congress 2019 – Exacerbations of airway diseases Year: 2019 Corticosteroids for community-acquired pneumonia: a critical view of the evidence Source: Eur Respir J 2016; 48: 984-986 Year: 2016 Early identification of patients at risk for acute respiratory distress syndrome among severe pneumonia: a retrospective cohort study Source: International Congress 2018 – Critically ill patients: prognostic factors and biomarkers Year: 2018 Does enhanced respiratory support affect clinical outcomes in ILD Patients with acute Respiratory failure? Source: International Congress 2017 – ILDs: clinical problems Year: 2017 Late-breaking abstract: Evaluation of CRP, PCT, clinical pulmonary infection score and pneumonia severity scores for the diagnosis and prognosis of nursing home acquired pneumonia Source: Annual Congress 2011 - Early diagnosis in primary care Year: 2011